静脈性下腿潰瘍(下腿潰瘍)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0671
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥212,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥636,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Venous Leg Ulcers (Crural ulcer) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural Ulcer) – Pipeline Review, H1 2020, provides an overview of the Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural Ulcer) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 5, 2, 1, 4 and 1 respectively.

Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural Ulcer) – Overview
Venous Leg Ulcers (Crural Ulcer) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural Ulcer) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural Ulcer) – Companies Involved in Therapeutics Development
Aurealis Therapeutics AG
CardioVascular BioTherapeutics Inc
CytoTools AG
Energenesis Biomedical Co Ltd
FirstString Research Inc
GangaGen Inc
Hypo-Stream Ltd
Ilkos Therapeutics Inc
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
QBiotics Ltd
Venous Leg Ulcers (Crural Ulcer) – Drug Profiles
AUP-16 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venous Leg Ulcers (Crural Ulcer) – Dormant Projects
Venous Leg Ulcers (Crural Ulcer) – Discontinued Products
Venous Leg Ulcers (Crural Ulcer) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Aurealis Therapeutics AG, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Energenesis Biomedical Co Ltd, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Hypo-Stream Ltd, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Ilkos Therapeutics Inc, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Mallinckrodt Plc, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Pipeline by QBiotics Ltd, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, H1 2020
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, H1 2020

【掲載企業】

Aurealis Therapeutics AG
CardioVascular BioTherapeutics Inc
CytoTools AG
Energenesis Biomedical Co Ltd
FirstString Research Inc
GangaGen Inc
Hypo-Stream Ltd
Ilkos Therapeutics Inc
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
QBiotics Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[静脈性下腿潰瘍(下腿潰瘍)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆